{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:28:58Z","timestamp":1780345738709,"version":"3.54.1"},"reference-count":94,"publisher":"Sociedade Brasileira de Cardiologia","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,13]]},"DOI":"10.36660\/abc.20250621","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:29:11Z","timestamp":1764091751000},"source":"Crossref","is-referenced-by-count":1,"title":["Diretriz Brasileira Baseada em Evid\u00eancias de 2025 para o Manejo da Obesidade e Preven\u00e7\u00e3o de Doen\u00e7as Cardiovasculares e Complica\u00e7\u00f5es Associadas \u00e0 Obesidade: Uma Declara\u00e7\u00e3o de Posicionamento de Cinco Sociedades M\u00e9dicas"],"prefix":"10.36660","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-8862","authenticated-orcid":false,"given":"Jos\u00e9 Francisco Kerr","family":"Saraiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-1735","authenticated-orcid":false,"given":"Cynthia M.","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana H.","family":"Rached","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5592-1603","authenticated-orcid":false,"given":"Simone Van de","family":"Sande-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-664X","authenticated-orcid":false,"given":"Viviane Z. Rocha","family":"Giraldez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8207-5521","authenticated-orcid":false,"given":"Fernando","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-6846","authenticated-orcid":false,"given":"Luciano F.","family":"Drager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-5065","authenticated-orcid":false,"given":"Bruno","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-6696","authenticated-orcid":false,"suffix":"Junior","given":"Wellington S. da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1987-8348","authenticated-orcid":false,"given":"Fabio R.","family":"Trujilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9549-7634","authenticated-orcid":false,"given":"Neuton","family":"Dornellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4369-5137","authenticated-orcid":false,"suffix":"Filho","given":"Ruy Lyra da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-5320","authenticated-orcid":false,"given":"Jo\u00e3o Eduardo N.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6501-1139","authenticated-orcid":false,"given":"Marcelo H. V.","family":"Assad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1278-0406","authenticated-orcid":false,"given":"Marcio C.","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-3386","authenticated-orcid":false,"given":"Paulo A. C.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1561-2926","authenticated-orcid":false,"given":"Rodrigo O.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7432-9085","authenticated-orcid":false,"given":"Rodrigo N.","family":"Lamounier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-8564","authenticated-orcid":false,"given":"Sergio E.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-3162","authenticated-orcid":false,"given":"Marcello C.","family":"Bertoluci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22636","reference":[{"key":"key20251125172908_B1","volume-title":"World Obesity Atlas 2025 [Internet]","author":"World Obesity Federation","year":"2025","unstructured":"World Obesity Federation. World Obesity Atlas 2025 [Internet]. London: World Obesity Federation; 2025 [cited 2025 Jul 15]. Available from: https:\/\/data.worldobesity.org\/publications\/?cat=23."},{"key":"key20251125172908_B2","first-page":"hcaf022","article-title":"Global Burden of Cardiovascular Diseases and its Risk Factors, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021","author":"Tan","year":"2025","unstructured":"Tan SCW, Zheng BB, Tang ML, Chu H, Zhao YT, Weng C. Global Burden of Cardiovascular Diseases and its Risk Factors, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. QJM. 2025:hcaf022. doi: 10.1093\/qjmed\/hcaf022.","journal-title":"QJM"},{"issue":"38","key":"key20251125172908_B3","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and Cardiovascular Disease: An ESC Clinical Consensus Statement","volume":"45","author":"Koskinas","year":"2024","unstructured":"Koskinas KC, van Craenenbroeck EM, Antoniades C, Bl\u00fcher M, Gorter TM, Hanssen H, et al. Obesity and Cardiovascular Disease: An ESC Clinical Consensus Statement. Eur Heart J. 2024;45(38):4063-98. doi: 10.1093\/eurheartj\/ehae508.","journal-title":"Eur Heart J"},{"issue":"21","key":"key20251125172908_B4","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despr\u00e9s JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-e1010. doi: 10.1161\/CIR.0000000000000973.","journal-title":"Circulation"},{"issue":"3","key":"key20251125172908_B5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.mayocp.2013.11.011","article-title":"A Pooled Analysis of Waist Circumference and Mortality in 650,000 Adults","volume":"89","author":"Cerhan","year":"2014","unstructured":"Cerhan JR, Moore SC, Jacobs EJ, Kitahara CM, Rosenberg PS, Adami HO, et al. A Pooled Analysis of Waist Circumference and Mortality in 650,000 Adults. Mayo Clin Proc. 2014;89(3):335-45. doi: 10.1016\/j.mayocp.2013.11.011.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"key20251125172908_B6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/ejcn.2013.61","article-title":"General and Abdominal Obesity Parameters and their Combination in Relation to Mortality: A Systematic Review and Meta-Regression Analysis","volume":"67","author":"Carmienke","year":"2013","unstructured":"Carmienke S, Freitag MH, Pischon T, Schlattmann P, Fankhaenel T, Goebel H, et al. General and Abdominal Obesity Parameters and their Combination in Relation to Mortality: A Systematic Review and Meta-Regression Analysis. Eur J Clin Nutr. 2013;67(6):573-85. doi: 10.1038\/ejcn.2013.61.","journal-title":"Eur J Clin Nutr"},{"issue":"18","key":"key20251125172908_B7","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/cvr\/cvab368","article-title":"Obesity Increases Heart Failure Incidence and Mortality: Observational and Mendelian Randomization Studies Totalling Over 1 Million Individuals","volume":"118","author":"Benn","year":"2023","unstructured":"Benn M, Marott SCW, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Obesity Increases Heart Failure Incidence and Mortality: Observational and Mendelian Randomization Studies Totalling Over 1 Million Individuals. Cardiovasc Res. 2023;118(18):3576-85. doi: 10.1093\/cvr\/cvab368.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"key20251125172908_B8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1089\/dtom.2025.0015","article-title":"Under New Criteria for Clinical Obesity, is Metabolic Obesity with Normal Body Weight Finally a Legitimate Disease Phenotype?","volume":"1","author":"Silva","year":"2025","unstructured":"Silva WS Jr. Under New Criteria for Clinical Obesity, is Metabolic Obesity with Normal Body Weight Finally a Legitimate Disease Phenotype? Diab Technol Obes Med. 2025;1(1):62-70. doi: 10.1089\/dtom.2025.0015.","journal-title":"Diab Technol Obes Med"},{"issue":"4","key":"key20251125172908_B9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S2213-8587(23)00058-X","article-title":"Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity","volume":"11","author":"Rubino","year":"2023","unstructured":"Rubino F, Batterham RL, Koch M, Mingrone G, le Roux CW, Farooqi IS, et al. Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity. Lancet Diabetes Endocrinol. 2023;11(4):226-8. doi: 10.1016\/S2213-8587(23)00058-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"key20251125172908_B10","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A New Framework for the Diagnosis, Staging and Management of Obesity in Adults","volume":"30","author":"Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, Halford JCG, Sbraccia P, Yumuk V, et al. A New Framework for the Diagnosis, Staging and Management of Obesity in Adults. Nat Med. 2024;30(9):2395-9. doi: 10.1038\/s41591-024-03095-3.","journal-title":"Nat Med"},{"issue":"5","key":"key20251125172908_B11","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/dom.16236","article-title":"Validation of the 2024 European Association for the Study of Obesity Diagnostic Criteria: A Comprehensive Assessment of Obesity-Related Mortality Risks","volume":"27","author":"Liu","year":"2025","unstructured":"Liu XY, Ge SY, Liu CA, Yin B, Bu ZT, Zheng X, et al. Validation of the 2024 European Association for the Study of Obesity Diagnostic Criteria: A Comprehensive Assessment of Obesity-Related Mortality Risks. Diabetes Obes Metab. 2025;27(5):2405-17. doi: 10.1111\/dom.16236.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"key20251125172908_B12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13098-025-01796-4","article-title":"CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): A New Proposition for an Integrated Multisystem Metabolic Disease","volume":"17","author":"Godoy-Matos","year":"2025","unstructured":"Godoy-Matos AF, Val\u00e9rio CM, Silva WS Jr, Araujo-Neto JM, Sposito AC, Suassuna JHR. CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): A New Proposition for an Integrated Multisystem Metabolic Disease. Diabetol Metab Syndr. 2025;17(1):218. doi: 10.1186\/s13098-025-01796-4.","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"key20251125172908_B13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and Validation of the American Heart Association's PREVENT Equations","volume":"149","author":"Khan","year":"2024","unstructured":"Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024;149(6):430-49. doi: 10.1161\/CIRCULATIONAHA.123.067626.","journal-title":"Circulation"},{"issue":"3","key":"key20251125172908_B14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-080891","article-title":"Results from a Cross-Specialty Consensus on Optimal Management of Patients with Chronic Kidney Disease (CKD): From Screening to Complications","volume":"14","author":"Arici","year":"2024","unstructured":"Arici M, Assaad-Khalil SH, Bertoluci MC, Choo J, Lee YJ, Madero M, et al. Results from a Cross-Specialty Consensus on Optimal Management of Patients with Chronic Kidney Disease (CKD): From Screening to Complications. BMJ Open. 2024;14(3):e080891. doi: 10.1136\/bmjopen-2023-080891.","journal-title":"BMJ Open"},{"issue":"24","key":"key20251125172908_B15","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement from the American Heart Association. Circulation. 2023;148(24):1982-2004. doi: 10.1161\/CIR.0000000000001191.","journal-title":"Circulation"},{"key":"key20251125172908_B16","volume-title":"PREVENT Online Calculator [Internet]","author":"American Heart Association","year":"2025","unstructured":"American Heart Association. PREVENT Online Calculator [Internet]. Dallas: American Heart Association; 2025 [cited 2025 Jul 15]. Available from: https:\/\/professional.heart.org\/en\/guidelines-and-statements\/prevent-calculator."},{"key":"key20251125172908_B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure","author":"Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021:S1071-9164(21)00050-6. doi: 10.1016\/j.cardfail.2021.01.022.","journal-title":"J Card Fail"},{"issue":"8","key":"key20251125172908_B18","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/s41591-024-03140-1","article-title":"An Evidence-Based Screening Tool for Heart Failure with Preserved Ejection Fraction: The HFpEF-ABA Score","volume":"30","author":"Reddy","year":"2024","unstructured":"Reddy YNV, Carter RE, Sundaram V, Kaye DM, Handoko ML, Tedford RJ, et al. An Evidence-Based Screening Tool for Heart Failure with Preserved Ejection Fraction: The HFpEF-ABA Score. Nat Med. 2024;30(8):2258-64. doi: 10.1038\/s41591-024-03140-1.","journal-title":"Nat Med"},{"issue":"3","key":"key20251125172908_B19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijcard.2013.08.088","article-title":"Obstructive Sleep Apnea and Risk of Cardiovascular Disease and All-Cause Mortality: A Meta-Analysis of Prospective Cohort Studies","volume":"169","author":"Wang","year":"2013","unstructured":"Wang X, Ouyang Y, Wang Z, Zhao G, Liu L, Bi Y. Obstructive Sleep Apnea and Risk of Cardiovascular Disease and All-Cause Mortality: A Meta-Analysis of Prospective Cohort Studies. Int J Cardiol. 2013;169(3):207-14. doi: 10.1016\/j.ijcard.2013.08.088.","journal-title":"Int J Cardiol"},{"key":"key20251125172908_B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.sleep.2020.03.011","article-title":"Association between Obstructive Sleep Apnoea Syndrome and the Risk of Cardiovascular Diseases: An Updated Systematic Review and Dose-Response Meta-Analysis","volume":"71","author":"Zhang","year":"2020","unstructured":"Zhang X, Fan J, Guo Y, Zhou J, Chen F, Jin Z, et al. Association between Obstructive Sleep Apnoea Syndrome and the Risk of Cardiovascular Diseases: An Updated Systematic Review and Dose-Response Meta-Analysis. Sleep Med. 2020;71:39-46. doi: 10.1016\/j.sleep.2020.03.011.","journal-title":"Sleep Med"},{"issue":"14","key":"key20251125172908_B21","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.124.072156","article-title":"Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure with Preserved Ejection Fraction in the Ambulatory Outpatient Setting","volume":"151","author":"Reddy","year":"2025","unstructured":"Reddy YNV, Tada A, Obokata M, Carter RE, Kaye DM, Handoko ML, et al. Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure with Preserved Ejection Fraction in the Ambulatory Outpatient Setting. Circulation. 2025;151(14):976-89. doi: 10.1161\/CIRCULATIONAHA.124.072156.","journal-title":"Circulation"},{"issue":"6","key":"key20251125172908_B22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin","volume":"346","author":"Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393-403. doi: 10.1056\/NEJMoa012512.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20251125172908_B23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes","volume":"369","author":"Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. N Engl J Med. 2013;369(2):145-54. doi: 10.1056\/NEJMoa1212914.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20251125172908_B24","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals with Type 2 Diabetes","volume":"34","author":"Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals with Type 2 Diabetes. Diabetes Care. 2011;34(7):1481-6. doi: 10.2337\/dc10-2415.","journal-title":"Diabetes Care"},{"issue":"6","key":"key20251125172908_B25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","article-title":"Morbidity and Mortality after Lifestyle Intervention for People with Impaired Glucose Tolerance: 30-Year Results of the Da Qing Diabetes Prevention Outcome Study","volume":"7","author":"Gong","year":"2019","unstructured":"Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, et al. Morbidity and Mortality after Lifestyle Intervention for People with Impaired Glucose Tolerance: 30-Year Results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452-61. doi: 10.1016\/S2213-8587(19)30093-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"key20251125172908_B26","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2337\/dc21-1805","article-title":"Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults with Type 2 Diabetes and Overweight\/Obesity: Results from the Look AHEAD Study","volume":"45","author":"Look AHEAD Research Group","year":"2022","unstructured":"Look AHEAD Research Group. Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults with Type 2 Diabetes and Overweight\/Obesity: Results from the Look AHEAD Study. Diabetes Care. 2022;45(5):1252-9. doi: 10.2337\/dc21-1805.","journal-title":"Diabetes Care"},{"issue":"11","key":"key20251125172908_B27","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the Magnitude of Weight Loss and Changes in Physical Fitness with Long-Term Cardiovascular Disease Outcomes in Overweight or Obese People with Type 2 Diabetes: A Post-Hoc Analysis of the Look AHEAD Randomised Clinical Trial","volume":"4","author":"Gregg","year":"2016","unstructured":"Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, Clark JM, et al. Association of the Magnitude of Weight Loss and Changes in Physical Fitness with Long-Term Cardiovascular Disease Outcomes in Overweight or Obese People with Type 2 Diabetes: A Post-Hoc Analysis of the Look AHEAD Randomised Clinical Trial. Lancet Diabetes Endocrinol. 2016;4(11):913-21. doi: 10.1016\/S2213-8587(16)30162-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"key20251125172908_B28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2213-8587(24)00363-2","article-title":"Estimating Direct Tissue Effects versus Weight Loss Effects of Incretin-Based Drugs for Obesity on Various Chronic Conditions","volume":"13","author":"Sattar","year":"2025","unstructured":"Sattar N, Lee MMY. Estimating Direct Tissue Effects versus Weight Loss Effects of Incretin-Based Drugs for Obesity on Various Chronic Conditions. Lancet Diabetes Endocrinol. 2025;13(4):347-54. doi: 10.1016\/S2213-8587(24)00363-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"key20251125172908_B29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric Surgery and Long-Term Cardiovascular Events","volume":"307","author":"Sj\u00f6str\u00f6m","year":"2012","unstructured":"Sj\u00f6str\u00f6m L, Peltonen M, Jacobson P, Sj\u00f6str\u00f6m CD, Karason K, Wedel H, et al. Bariatric Surgery and Long-Term Cardiovascular Events. JAMA. 2012;307(1):56-65. doi: 10.1001\/jama.2011.1914.","journal-title":"JAMA"},{"issue":"2","key":"key20251125172908_B30","first-page":"139","article-title":"Proposal of an Obesity Classification Based on Weight History: An Official Document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO)","volume":"66","author":"Halpern","year":"2022","unstructured":"Halpern B, Mancini MC, Melo ME, Lamounier RN, Moreira RO, Carra MK, et al. Proposal of an Obesity Classification Based on Weight History: An Official Document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO). Arch Endocrinol Metab. 2022;66(2):139-51. doi: 10.20945\/2359-3997000000465.","journal-title":"Arch Endocrinol Metab"},{"issue":"20","key":"key20251125172908_B31","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/eurheartj\/ehv486","article-title":"The Role of Obesity in Atrial Fibrillation","volume":"37","author":"Nalliah","year":"2016","unstructured":"Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The Role of Obesity in Atrial Fibrillation. Eur Heart J. 2016;37(20):1565-72. doi: 10.1093\/eurheartj\/ehv486.","journal-title":"Eur Heart J"},{"issue":"19","key":"key20251125172908_B32","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/jama.2013.280521","article-title":"Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients with Atrial Fibrillation: A Randomized Clinical Trial","volume":"310","author":"Abed","year":"2013","unstructured":"Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients with Atrial Fibrillation: A Randomized Clinical Trial. JAMA. 2013;310(19):2050-60. doi: 10.1001\/jama.2013.280521.","journal-title":"JAMA"},{"issue":"10","key":"key20251125172908_B33","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.amjcard.2019.08.009","article-title":"Meta-Analysis of Effect of Modest (\u226510%) Weight Loss in Management of Overweight and Obese Patients with Atrial Fibrillation","volume":"124","author":"Aldaas","year":"2019","unstructured":"Aldaas OM, Lupercio F, Han FT, Hoffmayer KS, Krummen D, Ho G, et al. Meta-Analysis of Effect of Modest (\u226510%) Weight Loss in Management of Overweight and Obese Patients with Atrial Fibrillation. Am J Cardiol. 2019;124(10):1568-74. doi: 10.1016\/j.amjcard.2019.08.009.","journal-title":"Am J Cardiol"},{"issue":"12","key":"key20251125172908_B34","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1111\/jce.16090","article-title":"The Effect of Weight Loss on Recurrence of Atrial Fibrillation after Catheter Ablation: A Systematic Review and Meta-Analysis","volume":"34","author":"Akhtar","year":"2023","unstructured":"Akhtar KH, Jafry AH, Beard C, Nasir YM, Agarwal S, Khan J, et al. The Effect of Weight Loss on Recurrence of Atrial Fibrillation after Catheter Ablation: A Systematic Review and Meta-Analysis. J Cardiovasc Electrophysiol. 2023;34(12):2514-26. doi: 10.1111\/jce.16090.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"23","key":"key20251125172908_B35","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2016.09.940","article-title":"Bariatric Surgery and the Risk of New-Onset Atrial Fibrillation in Swedish Obese Subjects","volume":"68","author":"Jamaly","year":"2016","unstructured":"Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sj\u00f6str\u00f6m L, Karason K. Bariatric Surgery and the Risk of New-Onset Atrial Fibrillation in Swedish Obese Subjects. J Am Coll Cardiol. 2016;68(23):2497-504. doi: 10.1016\/j.jacc.2016.09.940.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20251125172908_B36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1037\/amp0000517","article-title":"Lifestyle Modification Approaches for the Treatment of Obesity in Adults","volume":"75","author":"Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Butryn ML. Lifestyle Modification Approaches for the Treatment of Obesity in Adults. Am Psychol. 2020;75(2):235-51. doi: 10.1037\/amp0000517.","journal-title":"Am Psychol"},{"issue":"Suppl 1","key":"key20251125172908_B37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.14200","article-title":"Evidence-Based Weight Loss Interventions: Individualized Treatment Options to Maximize Patient Outcomes","volume":"23","author":"Bray","year":"2021","unstructured":"Bray GA, Ryan DH. Evidence-Based Weight Loss Interventions: Individualized Treatment Options to Maximize Patient Outcomes. Diabetes Obes Metab. 2021;23(Suppl 1):50-62. doi: 10.1111\/dom.14200.","journal-title":"Diabetes Obes Metab"},{"issue":"20","key":"key20251125172908_B38","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity","volume":"353","author":"Wadden","year":"2005","unstructured":"Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. N Engl J Med. 2005;353(20):2111-20. doi: 10.1056\/NEJMoa050156.","journal-title":"N Engl J Med"},{"issue":"18","key":"key20251125172908_B39","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","unstructured":"Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719-30. doi: 10.1056\/NEJMoa2028198.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20251125172908_B40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight Loss with Naltrexone SR\/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial","volume":"19","author":"Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O\u2019Neil PM, et al. Weight Loss with Naltrexone SR\/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial. Obesity. 2011;19(1):110-20. doi: 10.1038\/oby.2010.147.","journal-title":"Obesity"},{"issue":"14","key":"key20251125172908_B41","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial","volume":"325","author":"Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-13. doi: 10.1001\/jama.2021.1831.","journal-title":"JAMA"},{"issue":"11","key":"key20251125172908_B42","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: The SURMOUNT-3 Phase 3 Trial","volume":"29","author":"Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: The SURMOUNT-3 Phase 3 Trial. Nat Med. 2023;29(11):2909-18. doi: 10.1038\/s41591-023-02597-w.","journal-title":"Nat Med"},{"issue":"4","key":"key20251125172908_B43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13679-023-00534-z","article-title":"The Role of Lifestyle Modification with Second-Generation Anti-Obesity Medications: Comparisons, Questions, and Clinical Opportunities","volume":"12","author":"Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, et al. The Role of Lifestyle Modification with Second-Generation Anti-Obesity Medications: Comparisons, Questions, and Clinical Opportunities. Curr Obes Rep. 2023;12(4):453-73. doi: 10.1007\/s13679-023-00534-z.","journal-title":"Curr Obes Rep"},{"issue":"25","key":"key20251125172908_B44","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts","volume":"378","author":"Estruch","year":"2018","unstructured":"Estruch R, Ros E, Salas-Salvad\u00f3 J, Covas MI, Corella D, Ar\u00f3s F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi: 10.1056\/NEJMoa1800389.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20251125172908_B45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamainternmed.2022.6117","article-title":"Healthy Eating Patterns and Risk of Total and Cause-Specific Mortality","volume":"183","author":"Shan","year":"2023","unstructured":"Shan Z, Wang F, Li Y, Baden MY, Bhupathiraju SN, Wang DD, et al. Healthy Eating Patterns and Risk of Total and Cause-Specific Mortality. JAMA Intern Med. 2023;183(2):142-53. doi: 10.1001\/jamainternmed.2022.6117.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"key20251125172908_B46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13098-023-01037-6","article-title":"Position Statement on Nutrition Therapy for Overweight and Obesity: Nutrition Department of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO-2022)","volume":"15","author":"Pepe","year":"2023","unstructured":"Pepe RB, Lottenberg AM, Fujiwara CTH, Beyruti M, Cintra DE, Machado RM, et al. Position Statement on Nutrition Therapy for Overweight and Obesity: Nutrition Department of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO-2022). Diabetol Metab Syndr. 2023;15(1):124. doi: 10.1186\/s13098-023-01037-6.","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"key20251125172908_B47","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.amepre.2025.02.018","article-title":"Premature Mortality Attributable to Ultraprocessed Food Consumption in 8 Countries","volume":"68","author":"Nilson","year":"2025","unstructured":"Nilson EAF, Delpino FM, Batis C, Machado PP, Moubarac JC, Cediel G, et al. Premature Mortality Attributable to Ultraprocessed Food Consumption in 8 Countries. Am J Prev Med. 2025;68(6):1091-9. doi: 10.1016\/j.amepre.2025.02.018.","journal-title":"Am J Prev Med"},{"issue":"10077","key":"key20251125172908_B48","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 Years of Liraglutide versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals with Prediabetes: A Randomised, Double-Blind Trial","volume":"389","author":"le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, van Gaal L, et al. 3 Years of Liraglutide versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals with Prediabetes: A Randomised, Double-Blind Trial. Lancet. 2017;389(10077):1399-409. doi: 10.1016\/S0140-6736(17)30069-7.","journal-title":"Lancet"},{"issue":"3","key":"key20251125172908_B49","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.13125","article-title":"Liraglutide and Cardiovascular Outcomes in Adults with Overweight or Obesity: A Post Hoc Analysis from SCALE Randomized Controlled Trials","volume":"20","author":"Davies","year":"2018","unstructured":"Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Adults with Overweight or Obesity: A Post Hoc Analysis from SCALE Randomized Controlled Trials. Diabetes Obes Metab. 2018;20(3):734-9. doi: 10.1111\/dom.13125.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"key20251125172908_B50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi: 10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"10","key":"key20251125172908_B51","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"392","author":"Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-71. doi: 10.1056\/NEJMoa2410819.","journal-title":"N Engl J Med"},{"key":"key20251125172908_B52","doi-asserted-by":"crossref","first-page":"105782","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-Diabetic Drugs and Weight Loss in Patients with Type 2 Diabetes","volume":"171","author":"Lazzaroni","year":"2021","unstructured":"Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, et al. Anti-Diabetic Drugs and Weight Loss in Patients with Type 2 Diabetes. Pharmacol Res. 2021;171:105782. doi: 10.1016\/j.phrs.2021.105782.","journal-title":"Pharmacol Res"},{"issue":"1","key":"key20251125172908_B53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients","volume":"27","author":"Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. Diabetes Care. 2004;27(1):155-61. doi: 10.2337\/diacare.27.1.155.","journal-title":"Diabetes Care"},{"issue":"22","key":"key20251125172908_B54","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-Analysis","volume":"315","author":"Khera","year":"2016","unstructured":"Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-Analysis. JAMA. 2016;315(22):2424-34. doi: 10.1001\/jama.2016.7602.","journal-title":"JAMA"},{"issue":"5","key":"key20251125172908_B55","doi-asserted-by":"crossref","first-page":"1309.e7","DOI":"10.1053\/j.gastro.2017.12.024","article-title":"Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-Analysis","volume":"154","author":"Khera","year":"2018","unstructured":"Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, et al. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-Analysis. Gastroenterology. 2018;154(5):1309-19.e7. doi: 10.1053\/j.gastro.2017.12.024.","journal-title":"Gastroenterology"},{"issue":"10","key":"key20251125172908_B56","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients with Cardiovascular Risk Factors: A Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients with Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016;315(10):990-1004. doi: 10.1001\/jama.2016.1558.","journal-title":"JAMA"},{"issue":"6","key":"key20251125172908_B57","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13224","article-title":"Cardiovascular Safety of Naltrexone and Bupropion Therapy: Systematic Review and Meta-Analyses","volume":"22","author":"Sposito","year":"2021","unstructured":"Sposito AC, Bonilha I, Luchiari B, Benchimol A, Hohl A, Moura F, et al. Cardiovascular Safety of Naltrexone and Bupropion Therapy: Systematic Review and Meta-Analyses. Obes Rev. 2021;22(6):e13224. doi: 10.1111\/obr.13224.","journal-title":"Obes Rev"},{"key":"key20251125172908_B58","doi-asserted-by":"crossref","DOI":"10.20945\/2359-4292-2024-0422","article-title":"Pharmacologic Treatment of Obesity in Adults and its Impact on Comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)","volume":"68","author":"Moreira","year":"2024","unstructured":"Moreira RO, Valerio CM, Hohl A, Moulin C, Moura F, Trujilho FR, et al. Pharmacologic Treatment of Obesity in Adults and its Impact on Comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2024;68:e240422. doi: 10.20945\/2359-4292-2024-0422.","journal-title":"Arch Endocrinol Metab"},{"issue":"24","key":"key20251125172908_B59","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-32. doi: 10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"10","key":"key20251125172908_B60","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects","volume":"363","author":"James","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, Finer N, van Gaal LF, Maggioni AP, et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med. 2010;363(10):905-17. doi: 10.1056\/NEJMoa1003114.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20251125172908_B61","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/dc24-1533","article-title":"Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations with or Without Type 2 Diabetes and\/or Overweight or Obesity","volume":"48","author":"Lee","year":"2025","unstructured":"Lee M, Ghouri N, Misra A, Kang YM, Ruttler MK, Gerstein HC, et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations with or Without Type 2 Diabetes and\/or Overweight or Obesity. Diabetes Care. 2025;48(3):489-93. doi: 10.2337\/dc24-1533.","journal-title":"Diabetes Care"},{"issue":"10","key":"key20251125172908_B62","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Trials","volume":"9","author":"Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Trials. Lancet Diabetes Endocrinol. 2021;9(10):653-62. doi: 10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20251125172908_B63","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-Glucose Cotransporter Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials","volume":"372","author":"Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-Glucose Cotransporter Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. BMJ. 2021;372:m4573. doi: 10.1136\/bmj.m4573.","journal-title":"BMJ"},{"issue":"20","key":"key20251125172908_B64","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes","volume":"392","author":"McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001-12. doi: 10.1056\/NEJMoa2501006.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20251125172908_B65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-21. doi: 10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20251125172908_B66","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1164\/rccm.200805-669OC","article-title":"Lifestyle Intervention with Weight Reduction: First-Line Treatment in Mild Obstructive Sleep Apnea","volume":"179","author":"Tuomilehto","year":"2009","unstructured":"Tuomilehto HP, Sepp\u00e4 JM, Partinen MM, Peltonen M, Gylling H, Tuomilehto JO, et al. Lifestyle Intervention with Weight Reduction: First-Line Treatment in Mild Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2009;179(4):320-7. doi: 10.1164\/rccm.200805-669OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"key20251125172908_B67","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/archinternmed.2009.266","article-title":"A randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients with Type 2 Diabetes: the Sleep AHEAD Study","volume":"169","author":"Foster","year":"2009","unstructured":"Foster GD, Borradaile KE, Sanders MH, Millman R, Zammit G, Newman AB, et al. A randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients with Type 2 Diabetes: the Sleep AHEAD Study. Arch Intern Med. 2009;169(17):1619-26. doi: 10.1001\/archinternmed.2009.266.","journal-title":"Arch Intern Med"},{"issue":"4","key":"key20251125172908_B68","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.8212","article-title":"Effect of an Interdisciplinary Weight Loss and Lifestyle Intervention on Obstructive Sleep Apnea Severity: The INTERAPNEA Randomized Clinical Trial","volume":"5","author":"Carneiro-Barrera","year":"2022","unstructured":"Carneiro-Barrera A, Amaro-Gahete FJ, Guill\u00e9n-Riquelme A, Jurado-Fasoli L, S\u00e1ez-Roca G, Mart\u00edn-Carrasco C, et al. Effect of an Interdisciplinary Weight Loss and Lifestyle Intervention on Obstructive Sleep Apnea Severity: The INTERAPNEA Randomized Clinical Trial. JAMA Netw Open. 2022;5(4):e228212. doi: 10.1001\/jamanetworkopen.2022.8212.","journal-title":"JAMA Netw Open"},{"key":"key20251125172908_B69","doi-asserted-by":"crossref","first-page":"b4609","DOI":"10.1136\/bmj.b4609","article-title":"Effect of a Very Low Energy Diet on Moderate and Severe Obstructive Sleep Apnoea in Obese Men: A Randomised Controlled Trial","volume":"339","author":"Johansson","year":"2009","unstructured":"Johansson K, Neovius M, Lagerros YT, Harlid R, R\u00f6ssner S, Granath F, et al. Effect of a Very Low Energy Diet on Moderate and Severe Obstructive Sleep Apnoea in Obese Men: A Randomised Controlled Trial. BMJ. 2009;339:b4609. doi: 10.1136\/bmj.b4609.","journal-title":"BMJ"},{"issue":"8","key":"key20251125172908_B70","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of Liraglutide 3.0 mg in Individuals with Obesity and Moderate or Severe Obstructive Sleep Apnea: The SCALE Sleep Apnea Randomized Clinical Trial","volume":"40","author":"Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of Liraglutide 3.0 mg in Individuals with Obesity and Moderate or Severe Obstructive Sleep Apnea: The SCALE Sleep Apnea Randomized Clinical Trial. Int J Obes. 2016;40(8):1310-9. doi: 10.1038\/ijo.2016.52.","journal-title":"Int J Obes"},{"issue":"13","key":"key20251125172908_B71","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity","volume":"391","author":"Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-205. doi: 10.1056\/NEJMoa2404881.","journal-title":"N Engl J Med"},{"key":"key20251125172908_B72","volume-title":"FDA Approves First Medication for Obstructive Sleep Apnea [Internet]","author":"U.S. Food and Drug Administration","year":"2024","unstructured":"U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea [Internet]. [cited 2025 Jul 15]. Silver Spring: Food and Drug Administration; 2024 Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea."},{"issue":"10","key":"key20251125172908_B73","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1513\/AnnalsATS.202101-060OC","article-title":"Effect of Continuous Positive Airway Pressure on Weight and Local Adiposity in Adults with Obstructive Sleep Apnea: A Meta-Analysis","volume":"18","author":"Chen","year":"2021","unstructured":"Chen B, Drager LF, Peker Y, Vgontzas AN, Phillips CL, Hoyos CM, et al. Effect of Continuous Positive Airway Pressure on Weight and Local Adiposity in Adults with Obstructive Sleep Apnea: A Meta-Analysis. Ann Am Thorac Soc. 2021;18(10):1717-27. doi: 10.1513\/AnnalsATS.202101-060OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"17","key":"key20251125172908_B74","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/eurjpc\/zwad284","article-title":"Effects of Weight Loss in Heart Failure Patients with Overweight and Obesity: A Systematic Review and Meta-Analysis","volume":"30","author":"Chi","year":"2023","unstructured":"Chi M, Nie Y, Su Y, Wang N, Li A, Ma T, et al. Effects of Weight Loss in Heart Failure Patients with Overweight and Obesity: A Systematic Review and Meta-Analysis. Eur J Prev Cardiol. 2023;30(17):1906-21. doi: 10.1093\/eurjpc\/zwad284.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"key20251125172908_B75","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/heartjnl-2019-314770","article-title":"Complex Interaction of Obesity, Intentional Weight Loss and Heart Failure: A Systematic Review and Meta-Analysis","volume":"106","author":"Mahajan","year":"2020","unstructured":"Mahajan R, Stokes M, Elliott A, Munawar DA, Khokhar KB, Thiyagarajah A, et al. Complex Interaction of Obesity, Intentional Weight Loss and Heart Failure: A Systematic Review and Meta-Analysis. Heart. 2020;106(1):58-68. doi: 10.1136\/heartjnl-2019-314770.","journal-title":"Heart"},{"issue":"12","key":"key20251125172908_B76","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-84. doi: 10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"issue":"8 Pt 1","key":"key20251125172908_B77","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients with Obesity HFpEF Phenotype","volume":"11","author":"Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Christensen L, Davies M, et al. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients with Obesity HFpEF Phenotype. JACC Heart Fail. 2023;11(8 Pt 1):1000-10. doi: 10.1016\/j.jchf.2023.05.010.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"key20251125172908_B78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-37. doi: 10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"issue":"10354","key":"key20251125172908_B79","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 Inhibitors in Patients with Heart Failure: A Comprehensive Meta-Analysis of Five Randomised Controlled Trials","volume":"400","author":"Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 Inhibitors in Patients with Heart Failure: A Comprehensive Meta-Analysis of Five Randomised Controlled Trials. Lancet. 2022;400(10354):757-67. doi: 10.1016\/S0140-6736(22)01429-5.","journal-title":"Lancet"},{"issue":"5","key":"key20251125172908_B80","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of Liraglutide on Clinical Stability among Patients with Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial","volume":"316","author":"Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of Liraglutide on Clinical Stability among Patients with Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016;316(5):500-8. doi: 10.1001\/jama.2016.10260.","journal-title":"JAMA"},{"issue":"6","key":"key20251125172908_B81","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ehf2.12334","article-title":"Liraglutide and Weight Loss among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial","volume":"5","author":"Sharma","year":"2018","unstructured":"Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, et al. Liraglutide and Weight Loss among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial. ESC Heart Fail. 2018;5(6):1035-43. doi: 10.1002\/ehf2.12334.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"key20251125172908_B82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes (LIVE)-a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial","volume":"19","author":"Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A, et al. Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes (LIVE)-a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. Eur J Heart Fail. 2017;19(1):69-77. doi: 10.1002\/ejhf.657.","journal-title":"Eur J Heart Fail"},{"issue":"10454","key":"key20251125172908_B83","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the SELECT Trial","volume":"404","author":"Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the SELECT Trial. Lancet. 2024;404(10454):773-86. doi: 10.1016\/S0140-6736(24)01498-3.","journal-title":"Lancet"},{"issue":"22","key":"key20251125172908_B84","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide in Patients with Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction","volume":"82","author":"Butler","year":"2023","unstructured":"Butler J, Abildstr\u00f8m SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, et al. Semaglutide in Patients with Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2023;82(22):2087-96. doi: 10.1016\/j.jacc.2023.09.811.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20251125172908_B85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 Receptor Agonists on Blood Pressure, Heart Rate and Hypertension among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","volume":"110","author":"Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 Receptor Agonists on Blood Pressure, Heart Rate and Hypertension among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Res Clin Pract. 2015;110(1):26-37. doi: 10.1016\/j.diabres.2015.07.015.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"key20251125172908_B86","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/dom.16078","article-title":"One or Two? Comparison of the Cardiorenal effects between Combination Therapy and Monotherapy with SGLT2i or GLP1RA","volume":"27","author":"Zhang","year":"2025","unstructured":"Zhang M, Lin C, Cai X, Jiao R, Bai S, Li Z, et al. One or Two? Comparison of the Cardiorenal effects between Combination Therapy and Monotherapy with SGLT2i or GLP1RA. Diabetes Obes Metab. 2025;27(2):806-15. doi: 10.1111\/dom.16078.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"key20251125172908_B87","doi-asserted-by":"crossref","first-page":"761.e1","DOI":"10.1016\/j.amjmed.2024.04.032","article-title":"Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared with Monotherapy Improves Long-Term Survival: A Real-World Registry","volume":"137","author":"Garc\u00eda-Vega","year":"2024","unstructured":"Garc\u00eda-Vega D, Cinza-Sanjurjo S, Eiras S, Gonz\u00e1lez-Juanatey JR. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared with Monotherapy Improves Long-Term Survival: A Real-World Registry. Am J Med. 2024;137(8):761-9.e1. doi: 10.1016\/j.amjmed.2024.04.032.","journal-title":"Am J Med"},{"issue":"7","key":"key20251125172908_B88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003206","article-title":"Association of Bariatric Surgery with All-Cause Mortality and Incidence of Obesity-Related Disease at a Population Level: A Systematic Review and Meta-Analysis","volume":"17","author":"Wiggins","year":"2020","unstructured":"Wiggins T, Guidozzi N, Welbourn R, Ahmed AR, Markar SR. Association of Bariatric Surgery with All-Cause Mortality and Incidence of Obesity-Related Disease at a Population Level: A Systematic Review and Meta-Analysis. PLoS Med. 2020;17(7):e1003206. doi: 10.1371\/journal.pmed.1003206.","journal-title":"PLoS Med"},{"issue":"5","key":"key20251125172908_B89","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005126","article-title":"Gastric Bypass Surgery Produces a Durable Reduction in Cardiovascular Disease Risk Factors and Reduces the Long-Term Risks of Congestive Heart Failure","volume":"6","author":"Benotti","year":"2017","unstructured":"Benotti PN, Wood GC, Carey DJ, Mehra VC, Mirshahi T, Lent MR, et al. Gastric Bypass Surgery Produces a Durable Reduction in Cardiovascular Disease Risk Factors and Reduces the Long-Term Risks of Congestive Heart Failure. J Am Heart Assoc. 2017;6(5):e005126. doi: 10.1161\/JAHA.116.005126.","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"key20251125172908_B90","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1001\/jama.2018.14619","article-title":"Association between Bariatric Surgery and Macrovascular Disease Outcomes in Patients with Type 2 Diabetes and Severe Obesity","volume":"320","author":"Fisher","year":"2018","unstructured":"Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O\u2019Connor PJ, et al. Association between Bariatric Surgery and Macrovascular Disease Outcomes in Patients with Type 2 Diabetes and Severe Obesity. JAMA. 2018;320(15):1570-82. doi: 10.1001\/jama.2018.14619.","journal-title":"JAMA"},{"issue":"26","key":"key20251125172908_B91","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/eurheartj\/ehz295","article-title":"Surgical Obesity Treatment and the Risk of Heart Failure","volume":"40","author":"Jamaly","year":"2019","unstructured":"Jamaly S, Carlsson L, Peltonen M, Jacobson P, Karason K. Surgical Obesity Treatment and the Risk of Heart Failure. Eur Heart J. 2019;40(26):2131-8. doi: 10.1093\/eurheartj\/ehz295.","journal-title":"Eur Heart J"},{"issue":"12","key":"key20251125172908_B92","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1007\/s11695-023-06898-4","article-title":"The Effect of Bariatric Surgery on Patients with Heart Failure: A Systematic Review and Meta-Analysis","volume":"33","author":"Esparham","year":"2023","unstructured":"Esparham A, Mehri A, Hadian H, Taheri M, Moghadam HA, Kalantari A, et al. The Effect of Bariatric Surgery on Patients with Heart Failure: A Systematic Review and Meta-Analysis. Obes Surg. 2023;33(12):4125-36. doi: 10.1007\/s11695-023-06898-4.","journal-title":"Obes Surg"},{"issue":"3","key":"key20251125172908_B93","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.surg.2021.04.036","article-title":"Bariatric Surgery in Patients with Advanced Heart Failure: A Proposed Multi-Disciplinary pathway for Surgical Care in Medically Complex Patients","volume":"170","author":"Kindel","year":"2021","unstructured":"Kindel TL, Higgins RM, Lak K, Gould J, Kreuziger LB, Mohammed A, et al. Bariatric Surgery in Patients with Advanced Heart Failure: A Proposed Multi-Disciplinary pathway for Surgical Care in Medically Complex Patients. Surgery. 2021;170(3):659-63. doi: 10.1016\/j.surg.2021.04.036.","journal-title":"Surgery"},{"issue":"1","key":"key20251125172908_B94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13300-024-01659-7","article-title":"Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6","volume":"16","author":"Bain","year":"2025","unstructured":"Bain SC, Belmar N, Hoff ST, Husain M, Rasmussen S, Vilsb\u00f8ll T, et al. Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6. Diabetes Ther. 2025;16(1):15-28. doi: 10.1007\/s13300-024-01659-7.","journal-title":"Diabetes Ther"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:29:19Z","timestamp":1764091759000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/diretriz-brasileira-baseada-em-evidencias-de-2025-para-o-manejo-da-obesidade-e-prevencao-de-doencas-cardiovasculares-e-complicacoes-associadas-a-obesidade-uma-declaracao-de-posicionamento-de-cinco-so\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":94,"journal-issue":{"issue":"09","published-print":{"date-parts":[[2025,10,13]]}},"alternative-id":["10.36660\/abc.20250621 10.36660\/abc.20250621i"],"URL":"https:\/\/doi.org\/10.36660\/abc.20250621","relation":{"has-translation":[{"id-type":"doi","id":"10.36660\/abc.20250621i","asserted-by":"object"}]},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"value":"0066-782X","type":"print"},{"value":"1678-4170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e20250621"}}